Published in Lancet on April 22, 2006
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ (2007) 6.81
The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect (2008) 5.98
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS (2008) 4.40
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One (2008) 4.20
Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis (2008) 4.18
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS (2008) 3.71
Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health (2007) 3.68
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med (2009) 3.42
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in Rwanda. PLoS Med (2009) 3.18
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One (2011) 2.84
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med (2008) 2.82
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health (2009) 2.48
Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc (2009) 2.44
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Implementing family-focused HIV care and treatment: the first 2 years' experience of the mother-to-child transmission-plus program in Abidjan, Côte d'Ivoire. Trop Med Int Health (2009) 2.07
Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One (2011) 2.05
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action (2010) 2.04
Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med (2010) 2.00
Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J (2008) 2.00
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS (2007) 1.97
Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care. BMC Pediatr (2008) 1.96
HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med (2007) 1.94
Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study. AIDS (2013) 1.88
An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol (2010) 1.81
A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. PLoS One (2007) 1.80
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
Macronutrient supplementation for malnourished HIV-infected adults: a review of the evidence in resource-adequate and resource-constrained settings. Clin Infect Dis (2009) 1.75
Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health (2010) 1.75
Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr (2008) 1.73
Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambia. PLoS One (2010) 1.71
The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther (2007) 1.68
Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. AIDS (2010) 1.68
Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One (2010) 1.65
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther (2010) 1.63
Burnout and use of HIV services among health care workers in Lusaka District, Zambia: a cross-sectional study. Hum Resour Health (2009) 1.61
Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. BMC Infect Dis (2009) 1.58
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS (2009) 1.56
Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One (2011) 1.56
Trends and determinants of survival for over 200 000 patients on antiretroviral treatment in the Botswana National Program: 2002-2013. AIDS (2016) 1.54
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med (2011) 1.51
Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis (2009) 1.50
Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ (2013) 1.50
Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ (2008) 1.49
Children and HIV/AIDS: from research to policy and action in resource-limited settings. AIDS (2008) 1.49
Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res (2011) 1.47
Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One (2012) 1.46
Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J (2010) 1.46
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc (2010) 1.45
Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS Res Ther (2010) 1.43
Outcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment between 2004-2012. PLoS One (2016) 1.41
Men's heightened risk of AIDS-related death: the legacy of gendered HIV testing and treatment strategies. AIDS (2015) 1.39
Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS One (2011) 1.38
A model for extending antiretroviral care beyond the rural health centre. J Int AIDS Soc (2009) 1.38
Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health (2011) 1.37
Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr (2008) 1.36
Nutritional aspects of HIV-associated wasting in sub-Saharan Africa. Am J Clin Nutr (2010) 1.35
Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis (2008) 1.35
Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis (2009) 1.33
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis (2009) 1.30
Do targeted HIV programs improve overall care for pregnant women?: Antenatal syphilis management in Zambia before and after implementation of prevention of mother-to-child HIV transmission programs. J Acquir Immune Defic Syndr (2008) 1.29
Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS (2010) 1.28
Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health (2014) 1.26
Nurse led, primary care based antiretroviral treatment versus hospital care: a controlled prospective study in Swaziland. BMC Health Serv Res (2010) 1.26
Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières. Confl Health (2010) 1.25
SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. J Clin Microbiol (2014) 1.25
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol (2012) 1.24
Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One (2012) 1.23
Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res (2010) 1.22
High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc (2011) 1.21
Availability of supplies and motivations for accessing voluntary HIV counseling and testing services in Blantyre, Malawi. BMC Health Serv Res (2008) 1.21
HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc (2012) 1.21
Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr (2011) 1.21
Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. BMC Health Serv Res (2010) 1.20
Task-sharing of HIV care and ART initiation: evaluation of a mixed-care non-physician provider model for ART delivery in rural Malawi. PLoS One (2013) 1.17
High loss to followup and early mortality create substantial reduction in patient retention at antiretroviral treatment program in north-west ethiopia. ISRN AIDS (2012) 1.15
CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr (2009) 1.15
Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis (2011) 1.14
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 11.72
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis (2007) 5.27
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 5.13
Technologies for global health. Lancet (2012) 5.05
Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet (2010) 5.02
25 years of the WHO essential medicines lists: progress and challenges. Lancet (2003) 4.95
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Hepatitis E. Lancet (2012) 4.43
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
The threat of artemisinin-resistant malaria. N Engl J Med (2011) 4.15
Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med (2005) 3.68
Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS (2012) 3.50
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
The dynamics of measles in sub-Saharan Africa. Nature (2008) 3.35
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med (2013) 3.15
Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2012) 3.00
Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr (2011) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Concerns about injectable naltrexone for opioid dependence. Lancet (2011) 2.92
Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health (2010) 2.92
Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis (2011) 2.82
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis (2013) 2.51
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.45
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective? Trop Med Int Health (2006) 2.39
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc (2009) 2.31
Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis (2010) 2.24
Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics (2007) 2.24
Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis (2011) 2.21
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis (2007) 2.21
Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev (2013) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One (2011) 2.11
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06
Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? AIDS (2013) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS (2008) 2.04
Mortality, violence and lack of access to healthcare in the Democratic Republic of Congo. Disasters (2003) 2.04
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health (2011) 2.02
Evaluation of a 5-year programme to prevent mother-to-child transmission of HIV infection in Northern Uganda. J Trop Pediatr (2009) 2.02
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health (2010) 2.00
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med (2007) 1.94
The primacy of public health considerations in defining poor quality medicines. PLoS Med (2011) 1.91
Operative mortality in resource-limited settings: the experience of Medecins Sans Frontieres in 13 countries. Arch Surg (2010) 1.89
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS (2007) 1.88
Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy (2007) 1.88
Mind the gaps--the epidemiology of poor-quality anti-malarials in the malarious world--analysis of the WorldWide Antimalarial Resistance Network database. Malar J (2014) 1.86
Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria. Malar J (2009) 1.86
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Role and outcomes of community health workers in HIV care in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2013) 1.82
A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis (2006) 1.80
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS (2007) 1.77
Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J (2011) 1.76
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction (2008) 1.76
Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis (2007) 1.75
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr (2011) 1.74
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS (2003) 1.69
Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther (2013) 1.68
Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc (2012) 1.66
Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis (2009) 1.65
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS (2009) 1.60
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect (2010) 1.59
Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health (2014) 1.58
Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa. J Acquir Immune Defic Syndr (2012) 1.58
Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol (2010) 1.57
Mapping the aetiology of non-malarial febrile illness in Southeast Asia through a systematic review--terra incognita impairing treatment policies. PLoS One (2012) 1.56